Tirzepatide Therapy

Introduction to Tirzepatide

• Tirzepatide is a dual GIP/GLP-1 receptor agonist that causes significant gastrointestinal effects, including delayed gastric emptying, effects on central nervous system appetite centers, and changes in gut motility, which can be managed by reducing meal size, limiting alcohol and carbonated beverages, and avoiding high-fat diets, as recommended by the American Diabetes Association 1

Mechanism and Side Effects

• The American Diabetes Association recommends considering the potential gastrointestinal side effects of tirzepatide, including nausea, diarrhea, vomiting, constipation, and abdominal pain, when initiating therapy 1
• Gastrointestinal side effects are common during initiation and dose escalation of tirzepatide, with the most common side effects including nausea, diarrhea, vomiting, constipation, and abdominal pain, and management strategies include reducing meal size, limiting alcohol and carbonated beverages, avoiding high-fat diets, considering antiemetics for significant nausea, and using loperamide for troublesome diarrhea, as recommended by the European Association for the Study of Diabetes 2, 3, 1
• The frequency of common gastrointestinal adverse effects of tirzepatida includes:

4

• Antiemetics like ondansetron and loperamide may be used to manage nausea and diarrhea, respectively, as suggested by the American Gastroenterological Association and the American Diabetes Association 3, 5
• Patients should be monitored for severe abdominal pain, nausea and vomiting that doesn't resolve, and elevated lipase levels due to the risk of acute pancreatitis 6

Dosage and Administration

• The recommended starting dose of Mounjaro (tirzepatide) is 2.5 mg weekly, with gradual titration to 10 mg weekly (may increase to 15 mg if needed) 3
• Starting at a low dose (2.5mg) and titrating slowly can help manage gastrointestinal side effects, as recommended by the American Association of Clinical Endocrinologists 1
• Starting at lower doses (5 mg) and titrating upward slowly is recommended to minimize gastrointestinal effects, with a suggested approach by the European Association for the Study of Diabetes 1
• The target maintenance dose of tirzepatide should be selected based on clinical response and tolerability of side effects, with most patients achieving optimal results at 10-15 mg doses, according to the American Association of Clinical Endocrinologists 7

Contraindications and Warnings

• Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as noted by the American Diabetes Association, the American College of Clinical Endocrinologists, and the National Kidney Foundation 8, 4, 9, 10
• The American College of Endocrinology recommends monitoring for gallbladder disorders, including cholelithiasis and gallstone-related complications, when using tirzepatide 2
• The American Diabetes Association recommends monitoring for acute kidney injury due to dehydration from gastrointestinal side effects when using tirzepatide 2
• Patients should be assessed for history of pancreatitis, gallbladder disease, and renal function (creatinine, eGFR) before initiating Mounjaro (tirzepatide), as recommended by the American College of Endocrinology and the American Diabetes Association 3

Efficacy and Weight Loss

• Tirzepatide produces substantial weight loss, with a mean weight loss of 15% at 72 weeks in non-diabetic obese patients, and higher doses (15mg) can achieve up to 20.9% weight reduction, as reported by the American Heart Association 1
• Clinical studies have demonstrated that switching from dulaglutide to tirzepatide results in additional HbA1c reduction, with an average further reduction of 1.2%, enhanced weight loss, with an average additional loss of 3.6kg, and potential improvements in liver function parameters, according to the American College of Endocrinology 2
• Sudden discontinuation of tirzepatide results in regain of 50-67% of weight loss within 1 year, so long-term therapy is recommended for sustained benefits, as recommended by the International Diabetes Federation 2

Drug Interactions

• When used in combination with tirzepatide, insulin and insulin secretagogues may require dose adjustments to prevent hypoglycemia, as recommended by the American Diabetes Association, with a strength of evidence based on clinical trials 6, 11
• Sulfonylureas and glinides may have reduced effectiveness when used with tirzepatide, according to the European Association for the Study of Diabetes, with moderate-quality evidence 6, 11
• Medications that increase GI motility, such as prokinetic agents like metoclopramide, may reduce tirzepatide absorption, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases, with low-quality evidence 6, 11
• Administer oral medications at least 1 hour before tirzepatide injection when possible, as suggested by the American Association of Clinical Endocrinologists, to minimize interactions 6, 11
• Oral contraceptives may reduce the efficacy of tirzepatide due to delayed gastric emptying, and suggests switching to non-oral contraceptive or adding barrier method for 4 weeks after initiation and dose escalation, as recommended by the American College of Clinical Pharmacy 2

Nutrition and Lifestyle

• The Academy of Nutrition and Dietetics recommends considering resistance training and sufficient protein intake to prevent sarcopenia with significant weight loss when using tirzepatide 2
• More frequent glucose monitoring is recommended when starting or stopping potentially interacting medications, according to the International Diabetes Federation, with high-quality evidence 6, 11

Special Considerations

• No dose adjustment of tirzepatide is required in patients with renal impairment, even in end-stage renal disease, as stated by the National Kidney Foundation 2, 12
• Tirzepatide should be stopped at least one week before elective surgical procedures, and is not recommended during pregnancy or in women who may become pregnant, as stated by the American College of Obstetricians and Gynecologists and the American Diabetes Association 2, 5, 8
• Patients should be scheduled for follow-up 4 weeks after initiation of Mounjaro (tirzepatide) to monitor weight loss, glycemic control, and side effect burden, and adjust dosage as needed based on efficacy and tolerability, as recommended by the International Diabetes Federation and the American Diabetes Association 3, 4, 5
• Consider dose reduction rather than discontinuation if benefits outweigh side effects, and monitor for weight loss and glycemic control as expected benefits of tirzepatide therapy, as noted by the American Diabetes Association 4, 5